{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:34:45Z","timestamp":1792794885422,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015283","name":"Bloomberg Philanthropies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015283","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Specialty drug treatment programs should be a key setting to treat opioid use disorder (OUD), but most programs continue to not treat OUD patients with evidence-based medications for opioid use disorder (MOUD). COVID-19 introduced some flexibilities that could improve uptake of MOUD but ongoing barriers have not been examined. We examined barriers and facilitators to integrating MOUD post-COVID among specialty treatment programs in New Jersey.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Between March-July 2023, we conducted 14 semi-structured qualitative interviews with leadership and clinical staff of New Jersey specialty outpatient drug treatment programs, with varying levels of client MOUD uptake. Thematic analysis examined barriers and facilitators to providing MOUD in specialty treatment programs in the post-COVID-19 era.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Treatment providers revealed that financial barriers, including gaps in insurance coverage after COVID Medicaid expansions were terminated, continue to prevent MOUD use. Second, despite new buprenorphine telehealth flexibilities, a shortage of buprenorphine providers continues to limit ability to offer MOUD. Third, stigma against MOUD among clients, families, providers, and ancillary service providers such as housing programs continues to prevent MOUD initiation. Successful facilitators include expanding educational efforts on effectiveness of MOUD and harm reduction for clients and community members, forming specialized partnerships with pharmacies, and expanding care coordination efforts for those on MOUD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite efforts by federal and state governments, MOUD continues to be underutilized in specialty treatment settings, introducing significant risks for patients. Efforts should focus on reducing gaps in insurance coverage, improving provider knowledge of regulatory changes around MOUD, and supporting anti-stigma campaigns.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13722-025-00633-3","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T15:22:58Z","timestamp":1764948178000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["\u201cThey should be like penicillin\u201d: barriers to the integration of medications for opioid use disorder in specialty treatment programs"],"prefix":"10.1186","volume":"21","author":[{"given":"Isha K.","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jewyl","family":"Raikes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Saloner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth A.","family":"Feder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Krawczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"5","key":"633_CR1","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2105\/AJPH.2012.301049","volume":"103","author":"RP Schwartz","year":"2013","unstructured":"Schwartz RP, Gryczynski J, O\u2019Grady KE, Sharfstein JM, Warren G, Olsen Y, et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995\u20132009. Am J Public Health. 2013;103(5):917\u201322.","journal-title":"Am J Public Health"},{"issue":"2","key":"633_CR2","doi-asserted-by":"publisher","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"3","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622.","journal-title":"JAMA Netw Open"},{"issue":"9776","key":"633_CR3","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","volume":"377","author":"E Krupitsky","year":"2011","unstructured":"Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release Naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet Lond Engl. 2011;377(9776):1506\u201313.","journal-title":"Lancet Lond Engl"},{"key":"633_CR4","doi-asserted-by":"crossref","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;(2):CD002207.","DOI":"10.1002\/14651858.CD002207.pub4"},{"key":"633_CR5","unstructured":"State of New Jersey Department of Health. New Jersey SUDORS Overdose Mortality Data Explorer [Internet]. [cited 2025 Nov 13]. Available from: https:\/\/www.nj.gov\/health\/populationhealth\/opioid\/sudors.shtml"},{"key":"633_CR6","unstructured":"Substance Abuse and Mental Health Services Administration. National Substance Use and Mental Health Service Survey (N-SUMHSS). 2022: Data on Substance Use and Mental Health Treatment Facilities [Internet]. 2023 Sep. Report No.: PEP23-07-00\u2013002. Available from: https:\/\/www.samhsa.gov\/data\/"},{"key":"633_CR7","doi-asserted-by":"publisher","first-page":"108424","DOI":"10.1016\/j.jsat.2021.108424","volume":"132","author":"KT Solomon","year":"2022","unstructured":"Solomon KT, Bandara S, Reynolds IS, Krawczyk N, Saloner B, Stuart E, et al. Association between availability of medications for opioid use disorder in specialty treatment and use of medications among patients: A state-level trends analysis. J Subst Abuse Treat. 2022;132:108424.","journal-title":"J Subst Abuse Treat"},{"key":"633_CR8","doi-asserted-by":"crossref","unstructured":"Substance Abuse and Mental Health Services Administration. Clinical Use of Extended-Release Injectable Naltrexone in the Treatment of Opioid Use Disorder: A Brief Guide | SAMHSA Publications and Digital Products [Internet]. 2014 [cited 2024 Feb 22]. Available from: https:\/\/store.samhsa.gov\/product\/clinical-use-extended-release-injectable-naltrexone-treatment-opioid-use-disorder-brief","DOI":"10.12788\/cp.0387"},{"key":"633_CR9","doi-asserted-by":"publisher","first-page":"108176","DOI":"10.1016\/j.jsat.2020.108176","volume":"120","author":"RE Stewart","year":"2021","unstructured":"Stewart RE, Wolk CB, Neimark G, Vyas R, Young J, Tjoa C, et al. It\u2019s not just the money: the role of treatment ideology in publicly funded substance use disorder treatment. J Subst Abuse Treat. 2021;120:108176.","journal-title":"J Subst Abuse Treat"},{"key":"633_CR10","doi-asserted-by":"publisher","first-page":"108900","DOI":"10.1016\/j.jsat.2022.108900","volume":"144","author":"RE Stewart","year":"2023","unstructured":"Stewart RE, Cardamone NC, Mandell DS, Kwon N, Kampman KM, Knudsen HK, et al. Not in my treatment center: leadership\u2019s perception of barriers to MOUD adoption. J Subst Abuse Treat. 2023;144:108900.","journal-title":"J Subst Abuse Treat"},{"key":"633_CR11","doi-asserted-by":"publisher","first-page":"209351","DOI":"10.1016\/j.josat.2024.209351","volume":"162","author":"KN Burke","year":"2024","unstructured":"Burke KN, Krawczyk N, Li Y, Byrne L, Desai IK, Bandara S, et al. Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership. J Subst Use Addict Treat. 2024;162:209351.","journal-title":"J Subst Use Addict Treat"},{"issue":"5","key":"633_CR12","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s10488-013-0528-y","volume":"42","author":"LA Palinkas","year":"2015","unstructured":"Palinkas LA, Horwitz SM, Green CA, Wisdom JP, Duan N, Hoagwood K. Purposeful sampling for qualitative data collection and analysis in mixed method implementation research. Adm Policy Ment Health. 2015;42(5):533\u201344.","journal-title":"Adm Policy Ment Health"},{"issue":"1","key":"633_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1748-5908-4-50","volume":"4","author":"LJ Damschroder","year":"2009","unstructured":"Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4(1):50.","journal-title":"Implement Sci"},{"issue":"8","key":"633_CR14","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1080\/0142159X.2020.1755030","volume":"42","author":"ME Kiger","year":"2020","unstructured":"Kiger ME, Varpio L. Thematic analysis of qualitative data: AMEE guide 131. Med Teach. 2020;42(8):846\u201354.","journal-title":"Med Teach"},{"key":"633_CR15","unstructured":"KFF. KFF. 2019 [cited 2024 Mar 24]. State Medicaid Pharmacy Copay Requirements. Available from: https:\/\/www.kff.org\/other\/state-indicator\/state-medicaid-pharmacy-copay-requirements\/"},{"issue":"Suppl 3","key":"633_CR16","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s11606-020-06257-4","volume":"35","author":"K Mackey","year":"2020","unstructured":"Mackey K, Veazie S, Anderson J, Bourne D, Peterson K. Barriers and facilitators to the use of medications for opioid use disorder: a rapid review. J Gen Intern Med. 2020;35(Suppl 3):954\u201363.","journal-title":"J Gen Intern Med"},{"key":"633_CR17","doi-asserted-by":"publisher","first-page":"108784","DOI":"10.1016\/j.drugalcdep.2021.108784","volume":"225","author":"C Dunphy","year":"2021","unstructured":"Dunphy C, Peterson C, Zhang K, Jones CM. Do out-of-pocket costs influence retention and adherence to medications for opioid use disorder? Drug Alcohol Depend. 2021;225:108784.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"633_CR18","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1080\/07853890.2023.2171107","volume":"55","author":"B Andraka-Christou","year":"2023","unstructured":"Andraka-Christou B, Golan O, Totaram R, Ohama M, Saloner B, Gordon AJ, et al. Prior authorization restrictions on medications for opioid use disorder: trends in state laws from 2005 to 2019. Ann Med. 2023;55(1):514.","journal-title":"Ann Med"},{"issue":"1","key":"633_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13011-020-00312-3","volume":"15","author":"RL Haffajee","year":"2020","unstructured":"Haffajee RL, Andraka-Christou B, Attermann J, Cupito A, Buche J, Beck AJ. A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder. Subst Abuse Treat Prev Policy. 2020;15(1):69.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"11","key":"633_CR20","doi-asserted-by":"publisher","first-page":"e224001","DOI":"10.1001\/jamahealthforum.2022.4001","volume":"3","author":"AJ Abraham","year":"2022","unstructured":"Abraham AJ, Andrews CM, Harris SJ, Westlake MM, Grogan CM. Coverage and prior authorization policies for medications for opioid use disorder in medicaid managed care. JAMA Health Forum. 2022;3(11):e224001.","journal-title":"JAMA Health Forum"},{"issue":"5","key":"633_CR21","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1176\/appi.ps.202000565","volume":"73","author":"J McNeely","year":"2022","unstructured":"McNeely J, Schatz D, Olfson M, Appleton N, Williams AR. How physician workforce shortages are hampering the response to the opioid crisis. Psychiatr Serv. 2022;73(5):547\u201354.","journal-title":"Psychiatr Serv"},{"issue":"3","key":"633_CR22","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1080\/02791072.2019.1566583","volume":"51","author":"T Molfenter","year":"2019","unstructured":"Molfenter T, Fitzgerald M, Jacobson N, McCarty D, Quanbeck A, Zehner M. Barriers to buprenorphine expansion in ohio: A Time-Elapsed qualitative study. J Psychoact Drugs. 2019;51(3):272\u20139.","journal-title":"J Psychoact Drugs"},{"issue":"4","key":"633_CR23","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s11414-020-09706-4","volume":"47","author":"N Jacobson","year":"2020","unstructured":"Jacobson N, Horst J, Wilcox-Warren L, Toy A, Knudsen HK, Brown R, et al. Organizational facilitators and barriers to medication for opioid use disorder capacity expansion and use. J Behav Health Serv Res. 2020;47(4):439\u201348.","journal-title":"J Behav Health Serv Res"},{"issue":"1","key":"633_CR24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12909-023-04088-5","volume":"23","author":"JG Salvador","year":"2023","unstructured":"Salvador JG, Bola\u00f1os-Sacoman SL, Katzman JG, Morrison AE, Fox LE, Schneider JS, et al. Evaluation and guide for embedding opioid use disorder education in health professions\u2019 curricula. BMC Med Educ. 2023;23(1):135.","journal-title":"BMC Med Educ"},{"issue":"11","key":"633_CR25","doi-asserted-by":"publisher","first-page":"e1002969","DOI":"10.1371\/journal.pmed.1002969","volume":"16","author":"AC Tsai","year":"2019","unstructured":"Tsai AC, Kiang MV, Barnett ML, Beletsky L, Keyes KM, McGinty EE, et al. Stigma as a fundamental hindrance to the united States opioid overdose crisis response. PLoS Med. 2019;16(11):e1002969.","journal-title":"PLoS Med"},{"issue":"10","key":"633_CR26","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1080\/10826084.2021.1936051","volume":"56","author":"TH Witte","year":"2021","unstructured":"Witte TH, Jaiswal J, Mumba MN, Mugoya GCT. Stigma surrounding the use of medically assisted treatment for opioid use disorder. Subst Use Misuse. 2021;56(10):1467\u201375.","journal-title":"Subst Use Misuse"},{"key":"633_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jsat.2019.12.003","volume":"110","author":"KC Priest","year":"2020","unstructured":"Priest KC, Englander H, McCarty D. Now hospital leaders are paying attention: A qualitative study of internal and external factors influencing addiction consult services. J Subst Abuse Treat. 2020;110:59\u201365.","journal-title":"J Subst Abuse Treat"},{"key":"633_CR28","doi-asserted-by":"publisher","first-page":"100138","DOI":"10.1016\/j.dadr.2023.100138","volume":"6","author":"A Carl","year":"2023","unstructured":"Carl A, Pasman E, Broman MJ, Lister JJ, Agius E, Resko SM. Experiences of healthcare and substance use treatment provider-based stigma among patients receiving methadone. Drug Alcohol Depend Rep. 2023;6:100138.","journal-title":"Drug Alcohol Depend Rep"},{"issue":"1","key":"633_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/10783903211050121","volume":"28","author":"K Werder","year":"2022","unstructured":"Werder K, Curtis A, Reynolds S, Satterfield J. Addressing bias and stigma in the Language we use with persons with opioid use disorder: A narrative review. J Am Psychiatr Nurses Assoc. 2022;28(1):9\u201322.","journal-title":"J Am Psychiatr Nurses Assoc"},{"key":"633_CR30","unstructured":"LaBelle R, Weizman S, Sinkman D, Fields M. Recovery housing and civil rights laws: rights and obligations related to medications for opioid use disorder [Internet]. 2023 Dec. Available from: https:\/\/oneill.law.georgetown.edu\/publications\/recovery-housing-and-civil-rights-laws-rights-and-obligations-related-to-medications-for-opioid-use-disorder\/"},{"issue":"5","key":"633_CR31","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1080\/00952990.2023.2245123","volume":"49","author":"MS Subbaraman","year":"2023","unstructured":"Subbaraman MS, Mahoney E, Mericle A, Polcin D. Six-month length of stay associated with better recovery outcomes among residents of sober living houses. Am J Drug Alcohol Abuse. 2023;49(5):675\u201383.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"1","key":"633_CR32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12954-022-00589-6","volume":"19","author":"NA Bascou","year":"2022","unstructured":"Bascou NA, Haslund-Gourley B, Amber-Monta K, Samson K, Goss N, Meredith D, et al. Reducing the stigma surrounding opioid use disorder: evaluating an opioid overdose prevention training program applied to a diverse population. Harm Reduct J. 2022;19(1):5.","journal-title":"Harm Reduct J"},{"key":"633_CR33","doi-asserted-by":"publisher","first-page":"108729","DOI":"10.1016\/j.drugalcdep.2021.108729","volume":"224","author":"NJ Kazerouni","year":"2021","unstructured":"Kazerouni NJ, Irwin AN, Levander XA, Geddes J, Johnston K, Gostanian CJ, et al. Pharmacy-related buprenorphine access barriers: an audit of pharmacies in counties with a high opioid overdose burden. Drug Alcohol Depend. 2021;224:108729.","journal-title":"Drug Alcohol Depend"},{"key":"633_CR34","doi-asserted-by":"publisher","first-page":"102701","DOI":"10.1016\/j.drugpo.2020.102701","volume":"85","author":"HL Cooper","year":"2020","unstructured":"Cooper HL, Cloud DH, Freeman PR, Fadanelli M, Green T, Van Meter C, et al. Buprenorphine dispensing in an epicenter of the U.S. Opioid epidemic: A case study of the rural risk environment in Appalachian Kentucky. Int J Drug Policy. 2020;85:102701.","journal-title":"Int J Drug Policy"},{"key":"633_CR35","doi-asserted-by":"crossref","unstructured":"Thornton JD, Lyvers E, Scott V, Ginger) G, Dwibedi N. Pharmacists\u2019 readiness to provide naloxone in community pharmacies in West Virginia. J Am Pharm Assoc. 2017;57(2, Supplement):S12-S18.e4.","DOI":"10.1016\/j.japh.2016.12.070"},{"issue":"3","key":"633_CR36","doi-asserted-by":"publisher","first-page":"100641","DOI":"10.1016\/j.hjdsi.2022.100641","volume":"10","author":"RA Harris","year":"2022","unstructured":"Harris RA, Campbell K, Calderbank T, Dooley P, Aspero H, Maginnis J, et al. Integrating peer support services into primary care-based OUD treatment: lessons from the Penn integrated model. Healthc Amst Neth. 2022;10(3):100641.","journal-title":"Healthc Amst Neth"},{"issue":"1","key":"633_CR37","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1080\/08897077.2022.2095078","volume":"43","author":"HE Jack","year":"2022","unstructured":"Jack HE, Denisiuk ED, Collins BA, Stephens D, Blalock KL, Klein JW, et al. Peer providers and linkage with buprenorphine care after hospitalization: A retrospective cohort study. Subst Abuse. 2022;43(1):1308\u201316.","journal-title":"Subst Abuse"},{"issue":"3","key":"633_CR38","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1080\/14659891.2021.1938265","volume":"27","author":"S Mills Huffnagle","year":"2022","unstructured":"Mills Huffnagle S, Brennan G, Wicks K, Holden D, Kawasaki S. A comparison of patients with opioid use disorder receiving buprenorphine treatment with and without peer recovery support services. J Subst Use. 2022;27(3):266\u201371.","journal-title":"J Subst Use"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00633-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-025-00633-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00633-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:04:41Z","timestamp":1781622281000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13722-025-00633-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["633"],"URL":"https:\/\/doi.org\/10.1186\/s13722-025-00633-3","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"28 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was conducted in accordance with the norms of the Belmont Report. All study procedures were approved by the Johns Hopkins Bloomberg School of Public Health Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}